Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small...

Full description

Bibliographic Details
Main Authors: Zhulin Wang, Chunyao Huang, Wenbo Fan, Shaowu Sun, Kaiyuan Li, Xu Liu, Jiangtao Pu, Guoqing Zhang, Xiangnan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
EGFR fusion
EGFR amplification
rare mutations
lung adenocarcinoma
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1347282/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1347282/full

Similar Items